Los Angeles, USA, June 01, 2021 (GLOBE NEWSWIRE) -- COVID-19 Pipeline Diversifies as the COVID-19 Cases Soar and Demand for Effective Therapies Balloons | DelveInsight
Efforts in clinical development are being continuously made to advance toward finding safe and effective treatments and vaccines for COVID-19. After the approval of vaccines across the world, new anti-viral combinations and anti-inflammatory (including monoclonal antibodies) are under investigation.
DelveInsight’s ‘COVID-19 Pipeline Insights’ report offers exhaustive coverage of the emerging therapy landscape in different stages of development from pre-clinical till a late-end stage, along with dormant, inactive and abandoned therapeutic agents.
The COVID-19 Pipeline reports lay down a complete picture of the ongoing clinical trials, partnerships taking place in the domain, recent happenings in space and growth prospects across the COVID-19 domain.
Some of the key highlights from the COVID-19 Pipeline report:
- COVID-19 Pipeline report offers a rich analysis of 150+ key players and 200+ key therapies.
- COVID-19 pipeline comprises therapies in different stages of the clinical phase such as PSC 04, Ensovibep, Otezla, MXB-009, FB-2001, GC4419, ABBV-47D11, SNG001, CAP-1002, KIN001-CV, DPX COVID 19, and several others expected to get launched in the next decade.
- Some of the key companies engaged in expanding the COVID-19 Pipeline are Sorrento Therapeutics, Molecular Partners, Amgen, Maxwell Biosciences, Frontier Biotechnologies, Galera Therapeutics, AbbVie, Synairgen, Capricor, Kinarus, IMV, among others
- In May 2021, Moderna announced that the Phase 2/3 study of its COVID-19 vaccine (mRNA-1273) in adolescents has met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination and will submit results to the U.S. FDA and regulators globally in early June and request authorization.
- In May 2021, Synairgen developing an inhaled formulation of interferon beta (SNG001) as a broad-spectrum antiviral for the treatment of severe viral lung infections, currently in COVID-19 trials in the hospital and community settings, announces results from in vitro studies showing the antiviral activity of SNG001 against two SARS-CoV-2 variants.
- In May 2021, Celltrion has reported that its regdanvimab (CT-P59) demonstrated neutralising potency against emerging SARS-CoV-2 variants first-detected in New York, US (B.1.526), Nigeria (B.1.525) and India (B.1.617).
- Chinese company CanSino Biologics is set to commence clinical trials of a Covid-19 vaccine that can be administered through inhalation.
- In May 2021, Novartis and Molecular Partners said that it will start the clinical trial EMPATHY, a Phase II and III study, to explore the use of its DARPin therapeutic candidate ensovibep (MP0420) for the treatment of COVID-19. Novartis will conduct the clinical trial program for ensovibep, with Molecular Partners as a sponsor of the studies.
Request for Sample to know more about the therapies that are set to grab maximum patient pool @ COVID-19 Emerging Therapies and Forecast
A Pandemic that started in late 2019, COVID-19 has affected more than 160 million people worldwide. It is an infectious disease caused by a newly discovered coronavirus SARS-CoV-2. It affects the upper respiratory tract (sinuses, nose, and throat) or lower respiratory tract (windpipe and lungs) and spreads the same way other coronaviruses do, mainly through person-to-person contact.
For more information on emerging drugs, visit COVID-19 Pipeline Analysis
| Drug | Company | Phase | MoA | RoA |
| PSC 04 | Sorrento Therapeutics | Phase I | Cell replacements | Intravenous |
| Ensovibep | Molecular Partners | Phase II/III | Virus internalisation inhibitors | Infusion |
| Otezla | Amgen | Phase III | Type 4 cyclic nucleotide phosphodiesterase inhibitors | Oral |
| MXB-009 | Maxwell Biosciences | Preclinical | Viral envelope protein inhibitors | NA |
| FB-2001 | Frontier Biotechnologies | Phase I | Undefined mechanism | Intravenous |
| GC4419 | Galera Therapeutics | Phase II | Antioxidants | Intravenous |
| ABBV-47D11 | AbbVie | Phase I | Virus internalisation inhibitors | Intravenous |
| SNG001 | Synairgen | Phase III | Immunostimulants; Interferon beta-1a replacements | Inhalation |
| CAP-1002 | Capricor | Phase III | Cell replacements | Intravenous |
| KIN001-CV | Kinarus | Phase III | P38 mitogen-activated protein kinase inhibitors; Peroxisome proliferator-activated receptor gamma agonists | Oral |
| DPX COVID 19 | IMV | Preclinical | Immunostimulants | NA |
| VERU-111 | Veru Inc. | Phase III | Tubulin polymerisation inhibitors | Oral |
Request for Sample to know more @ COVID-19 Pipeline Analysis, Key Companies and Futuristic Trends
COVID-19 Therapeutic Assessment
The COVID-19 Pipeline report proffers detailed insights into active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.
By Product Type
- Mono
- Combination
By Stage
- Discovery
- Pre-clinical
- IND
- Phase I
- Phase II
- Phase III
- Pre-registration
By Molecule Type
- Small Molecule
- Gene Therapy
- Stem Cell Therapy
- Vaccines
- Monoclonal antibodies
- Proteins and Peptides
By Route of Administration
- Intravenous
- Inhalation
- Oral
- Subcutaneous
- Intranasal
- Intravascular
- Intradermal
By Mechanism of Action
- Interferon beta-1a replacements
- P38 mitogen-activated protein kinase inhibitors
- Cell replacements
- Type 4 cyclic nucleotide phosphodiesterase inhibitors
- Virus internalisation inhibitors
- Immunostimulants
- Undefined mechanism
- Superoxide dismutase modulators
- Viral envelope protein inhibitors
By Targets
- Interferon beta-1a
- P38 mitogen-activated protein kinase
- Type 4 cyclic nucleotide phosphodiesterase
- Superoxide dismutase
- Viral envelope protein
Get in touch with our Business executive for Informative Business Decisions, Licensing Services and Consulting Solutions
Scope of the Report
Coverage: Global
Key Players: Sorrento Therapeutics, Molecular Partners, Amgen, Maxwell Biosciences, Frontier Biotechnologies, Galera Therapeutics, AbbVie, Synairgen, Capricor, Kinarus, IMV, RedHill Biopharma, SAb Biotherapeutics, Adagio Therapeutics, Valneva, Novavax, Inovio Pharmaceuticals, VBI Vaccines, Rigel Pharmaceuticals, Translate Bio, Evelo Biosciences, Cocrystal Pharma, Icosavax, Atea Pharmaceuticals, NovaLead among others.
Key COVID-19 Pipeline Therapies: PSC 04, Ensovibep, Otezla, MXB-009, FB-2001, GC4419, ABBV-47D11, SNG001, CAP-1002, KIN001-CV, DPX COVID 19, PTC-299, RHB-107, SAB-185, ADG20, VLA2001, NVX-CoV2373, INO-4800, VBI-2902, Fostamatinib, MRT5500, EDP-1815, CDI-45205, IVX-411, AT‐527, NLP21 among others.
Reach out @ COVID-19 Pipeline: Novel therapies and Emerging technologies
Table of Contents
| 1 | Report Introduction |
| 2 | COVID-19 (CoronaVirus) Disease Overview |
| 3 | COVID-19 Pipeline Outlook |
| 4 | Comparative Analysis |
| 5 | COVID-19 Therapeutic Products in Clinical Stage |
| 6 | COVID-19 Therapeutic Products in Non-clinical Stage |
| 7 | COVID-19 Therapeutic Pipeline Analysis |
| 8 | Inactive COVID-19 Pipeline Products |
| 9 | Appendix |
| 10 | Report Methodology |
| 11 | Consulting Services |
| 12 | Disclaimer |
| 13 | About DelveInsight |
Visit to know more of what’s covered @ COVID-19 Emerging Therapies, Treatments and Ongoing Clinical Trials
Related Reports
Covid 19 Therapeutic Pipeline Vaccines
DelveInsight’s ‘COVID-19 (Novel Coronavirus 19) - Therapeutic Pipeline for Vaccines - 2020’ report provides comprehensive insights about 50+ companies and 60+ Vaccine based products in the COVID-19 pipeline landscape.
Covid 19 Novel Coronavirus 19 Therapeutic Pipeline Vaccines Diagnostics Competitive Landscape
Companies such as Gilead Sciences, Roche, Sanofi, Regeneron Moderna, Novavax, Medicago Inc., Altimmune, APEIRON Biologics, Inovio Pharmaceuticals and GlaxoSmithKline are a few of the players working towards developing therapies for COVID-19.
Epstein–Barr virus (EBV) Market
DelveInsight’s ‘Epstein–Barr virus (EBV) – Market Insights, Epidemiology, and Market Forecast—2030’ report offers a comprehensive analysis of epidemiology, treatments and pipeline therapies with key companies including Atara Biotherapeutics, AlloVir, Tessa Therapeutics, Viracta Therapeutics, Seagen, RAPT Therapeutics, Merck, Eutilex, Atara Biotherapeutics, Labolife, and others.
Epstein-Barr Virus-associated Post-Transplant Lymphoproliferative Disease Market
DelveInsight's "Epstein-Barr Virus-associated Post-Transplant Lymphoproliferative Disease - Market Insights, Epidemiology, and Market Forecast-2030" report.
Parainfluenza Virus Infection Market
DelveInsight's "Parainfluenza Virus Infection - Market Insights, Epidemiology, and Market Forecast-2030" report offers a comprehensive analysis of epidemiology, treatments and pipeline therapies with key companies including Novartis, Pfizer, Brazion Therapeutics, among others.
Rabies Virus Market
DelveInsight's "Rabies Virus - Market Insights, Epidemiology, and Market Forecast-2030" report.
Respiratory Syncytial Virus Market
DelveInsight's "Respiratory syncytial virus (RSV) - Market Insights, Epidemiology, and Market Forecast-2030" report.
Related Posts
COVID-19 Vaccine Outlook and Trials
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News